Previous 10 | Next 10 |
Penny Stocks To Watch During Q2 2020 Penny Stocks are some of the most sought after equities by day traders. Aside from options, these cheap stocks are some of the only ones that can generate massive returns within a matter of hours. Given that volatility, they’re not for everyone. Bu...
Gainers: Trevi Therapeutics (NASDAQ: TRVI ) +109% . More news on: Trevi Therapeutics, Inc., SG Blocks, Inc., Greenland Technologies Holding Corporation, Stocks on the move, , Read more ...
Amarin (NASDAQ: AMRN) shares were crashing on Tuesday, plunging 69.8% lower as of 9:55 a.m. The steep decline came after the U.S. District Court for the District of Nevada ruled in favor of generic-drug companies and invalidated Amarin's patent for Vascepa, which is approved by the FDA for t...
Amarin (NASDAQ: AMRN ) -68% after court decision on Vascepa. More news on: Amarin Corporation plc, Delphi Technologies PLC, SuperCom Ltd., Stocks on the move, , Read more ...
Apellis Pharmaceuticals (NASDAQ: APLS ) initiated with Outperform rating and $54 (88% upside) price target at BMO. More news on: Apellis Pharmaceuticals, Inc., Arena Pharmaceuticals, Inc., HEXO Corp., Healthcare stocks news, Stocks on the move, , Read more ...
DUBLIN, Ireland and BRIDGEWATER, N.J., March 31, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), hosted a webcast yesterday to discuss important data with study authors who presented at the American College of Cardiology’s 69 th Annual Scientific Session Together With...
Amarin (AMRN), a few hours ago, received a body blow in the form of a controversial judgment from a Nevada judge that ruined the stock, decimated thousands of retail investor portfolios, shattered the reputation of scores of analysts, and gave a thumbs-up to a couple of freeloading generic com...
Shares of Amarin (NASDAQ: AMRN) were down 68% at 7:27 p.m. EDT in after hours trading, after a judge in the U.S. District Court of Nevada ruled for generic-drug makers Hikma Pharmaceuticals (OTC: HKMPY) and Dr. Reddy's Laboratories (NYSE: RDY) in a lawsuit with Amarin over paten...
DUBLIN, Ireland and BRIDGEWATER, N.J., March 30, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today commented on the United States District Court for the District of Nevada’s ruling in favor of the generic companies in the company’s patent litigation against t...
Amarin (NASDAQ: AMRN ) has lost its patent battle against generics. More news on: Amarin Corporation plc, Healthcare stocks news, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...